Open Orphan PLC Exercise of Warrants and Issue of Shares (3463N)

TIDMORPH

RNS Number : 3463N

Open Orphan PLC

23 September 2019

Open Orphan Plc

("Open Orphan" or the "Company")

Exercise of Warrants and Issue of Shares

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company has received notices of exercise of warrants over 539,654 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") at a price of 0.1 pence per share for 191,051 ordinary shares and at a price of 2.2 pence per share for 348,603 ordinary shares. The gross proceeds of this exercise received by the Company amounts to GBP7,860.33.

Following the warrant exercise, the outstanding warrants over Ordinary Shares are as follows:

 
 Number of Ordinary Shares   Exercise Price per        Expiry Date 
                              share 
--------------------------  -------------------  ----------------- 
 166,666                     30 pence                  6 June 2021 
 1,759,752                   0.1 pence            10 December 2023 
 3,210,940                   2.2 pence            10 December 2023 
 1,607,142                   5.6 pence                27 June 2024

Total Voting Rights

The Company has made application for 539,654 new Ordinary Shares, to be issued and allotted as a result of the warrant exercise set out above, to be admitted to trading on AIM and Euronext Growth. Admission is expected to occur at 8.00 a.m. on 27 September 2019.

Following the admission of 539,654 new Ordinary Shares, the Company's total issued ordinary share capital will consist of 254,572,567 Ordinary Shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Open Orphan Plc Tel: +353 1 644 0007

Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900

John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363

Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980

Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOEZXLFLKKFXBBD

(END) Dow Jones Newswires

September 23, 2019 10:39 ET (14:39 GMT)

Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Apr 2024 to May 2024